Cargando…

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Diabetic kidney disease (DKD) is the most common cause of end stage renal disease. The comprehensive management of DKD depends on combined target-therapies for hyperglycemia, hypertension, albuminuria, and hyperlipaemia, etc. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, the most recently deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Honghong, Zhou, Baoqin, Xu, Gaosi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434580/
https://www.ncbi.nlm.nih.gov/pubmed/28511711
http://dx.doi.org/10.1186/s12933-017-0547-1
_version_ 1783237075289505792
author Zou, Honghong
Zhou, Baoqin
Xu, Gaosi
author_facet Zou, Honghong
Zhou, Baoqin
Xu, Gaosi
author_sort Zou, Honghong
collection PubMed
description Diabetic kidney disease (DKD) is the most common cause of end stage renal disease. The comprehensive management of DKD depends on combined target-therapies for hyperglycemia, hypertension, albuminuria, and hyperlipaemia, etc. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, the most recently developed oral hypoglycemic agents acted on renal proximal tubules, suppress glucose reabsorption and increase urinary glucose excretion. Besides improvements in glycemic control, they presented excellent performances in direct renoprotective effects and the cardiovascular (CV) safety by decreasing albuminuria and the independent CV risk factors such as body weight and blood pressure, etc. Simultaneous use of SGLT-2 inhibitors and renin–angiotensin–aldosterone system (RAAS) blockers are novel strategies to slow the progression of DKD via reducing inflammatory and fibrotic markers induced by hyperglycaemia more than either drug alone. The available population and animal based studies have described SGLT2 inhibitors plus RAAS blockers. The present review was to systematically review the potential renal benefits of SGLT2 inhibitors combined with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, mineralocorticoid receptor antagonists, and especially the angiotensin-converting enzyme inhibitors/angiotensin receptor blockers.
format Online
Article
Text
id pubmed-5434580
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54345802017-05-18 SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease Zou, Honghong Zhou, Baoqin Xu, Gaosi Cardiovasc Diabetol Review Diabetic kidney disease (DKD) is the most common cause of end stage renal disease. The comprehensive management of DKD depends on combined target-therapies for hyperglycemia, hypertension, albuminuria, and hyperlipaemia, etc. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, the most recently developed oral hypoglycemic agents acted on renal proximal tubules, suppress glucose reabsorption and increase urinary glucose excretion. Besides improvements in glycemic control, they presented excellent performances in direct renoprotective effects and the cardiovascular (CV) safety by decreasing albuminuria and the independent CV risk factors such as body weight and blood pressure, etc. Simultaneous use of SGLT-2 inhibitors and renin–angiotensin–aldosterone system (RAAS) blockers are novel strategies to slow the progression of DKD via reducing inflammatory and fibrotic markers induced by hyperglycaemia more than either drug alone. The available population and animal based studies have described SGLT2 inhibitors plus RAAS blockers. The present review was to systematically review the potential renal benefits of SGLT2 inhibitors combined with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, mineralocorticoid receptor antagonists, and especially the angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. BioMed Central 2017-05-16 /pmc/articles/PMC5434580/ /pubmed/28511711 http://dx.doi.org/10.1186/s12933-017-0547-1 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Zou, Honghong
Zhou, Baoqin
Xu, Gaosi
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
title SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
title_full SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
title_fullStr SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
title_full_unstemmed SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
title_short SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
title_sort sglt2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434580/
https://www.ncbi.nlm.nih.gov/pubmed/28511711
http://dx.doi.org/10.1186/s12933-017-0547-1
work_keys_str_mv AT zouhonghong sglt2inhibitorsanovelchoiceforthecombinationtherapyindiabetickidneydisease
AT zhoubaoqin sglt2inhibitorsanovelchoiceforthecombinationtherapyindiabetickidneydisease
AT xugaosi sglt2inhibitorsanovelchoiceforthecombinationtherapyindiabetickidneydisease